MEK inhibitors allosterically inhibit MEK, leading to cell death, and BRAF inhibitors target BRAF kinase and interfere with the mitogen-activated protein kinase signaling pathway that is responsible for the proliferation of melanoma cells. Studies have shown promising results with anti-CTLA-4 and anti-PD-1 therapy with nivolumab, pembrolizumab, and ipilimumab, with intracranial objective response rates ranging from 16% to 57% with acceptable toxicities [8-11]. This evidence concerns the gene BRAF and melanoma.